Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

miR-15a and 16-1 Are Downregulated in CD4(+) T Cells of Multiple Sclerosis Relapsing Patients

Full text
Author(s):
Cetrulo Lorenzi, Julio Cesar [1, 2] ; Brum, Doralina G. [3] ; Zanette, Dalila L. [1, 2] ; Alves Souza, Alessandra de Paula [2, 4] ; Barbuzano, Fernanda Goncalves [2] ; dos Santos, Antonio Carlos [5] ; Barreira, Amilton Antunes [3] ; Silva, Jr., Wilson Araujo [1, 2]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Dept Genet, Med Sch Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
[2] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Ribeirao Preto - Brazil
[3] Univ Sao Paulo, Dept Neurosci, Med Sch Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
[4] Univ Sao Paulo, Dept Immunol, Med Sch Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
[5] Univ Sao Paulo, Dept Internal Med, Med Sch Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
Total Affiliations: 5
Document type: Journal article
Source: International Journal of Neuroscience; v. 122, n. 8, p. 466-471, AUG 2012.
Web of Science Citations: 32
Abstract

The pathology of relapsing-remitting multiple sclerosis (RR-MS) is largely attributed to activated autoreactive effector T lymphocytes. The influence of microRNAs on the immune response has been shown to occur in different pathways of lymphocyte differentiation and function. Here, the expression of the miRNAs miR-15a/161 in PBMC, CD4(+), and CD8(+) from RR-MS patients has been investigated. BCL2, a known miR-15a/16-1 target, has also been analyzed. The results have shown that miR-15a/16-1 is downregulated in CD4(+) T cells, whereas BCL2 is highly expressed in RR-MS patients only. Our data suggest that miR-15a/16-1 can also modulate the BCL2 gene expression in CD4(+) T cells from RR-MS patients, thereby affecting apoptosis processes. (AU)

FAPESP's process: 98/14247-6 - Center for Research on Cell-Based Therapy
Grantee:Marco Antonio Zago
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 10/00310-1 - miRNA signature of T lymphocyte subpopulations from healthy and multiple sclerosis patients
Grantee:Julio Cesar Cetrulo Lorenzi
Support type: Scholarships in Brazil - Doctorate